Pharmaceutical Technology on MSN

BMS secures FDA acceptance for Camzyos sNDA

The new application was based on results from the Phase III SCOUT-HCM trial.
Folks who regularly exercise can lower their risk of heart attack and heart failure linked to a genetic heart condition, a ...
Learn which common medications you need to avoid when you have oHCM, including some for blood pressure and erectile ...
European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, ...
Cardiomyopathy can be a diverse diagnosis. There are many different types -- some inherited, others due to injury to the heart, treatment side effects, pregnancy, and a range of other causes. The ...
Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that targeting the genetic cause of disease improved cellular abnormalities and ...
From next-generation medications to groundbreaking gene therapies and nonsurgical procedures, explore the pipeline of treatments currently being tested for oHCM.
Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on ...